ZA201203551B - Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites - Google Patents

Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Info

Publication number
ZA201203551B
ZA201203551B ZA2012/03551A ZA201203551A ZA201203551B ZA 201203551 B ZA201203551 B ZA 201203551B ZA 2012/03551 A ZA2012/03551 A ZA 2012/03551A ZA 201203551 A ZA201203551 A ZA 201203551A ZA 201203551 B ZA201203551 B ZA 201203551B
Authority
ZA
South Africa
Prior art keywords
mva
insertion sites
virus containing
recombinant modified
vaccinia
Prior art date
Application number
ZA2012/03551A
Other languages
English (en)
Inventor
Bernard Moss
Patricia L Earl
Linda S Wyatt
Original Assignee
The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer filed Critical The U S A As Represented By The Secretary Dept Of Health And Human Services Office Of Tech Transfer
Publication of ZA201203551B publication Critical patent/ZA201203551B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2012/03551A 2009-10-16 2012-05-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites ZA201203551B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25232609P 2009-10-16 2009-10-16
PCT/US2010/052929 WO2011047324A1 (en) 2009-10-16 2010-10-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Publications (1)

Publication Number Publication Date
ZA201203551B true ZA201203551B (en) 2013-01-30

Family

ID=43297031

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/03551A ZA201203551B (en) 2009-10-16 2012-05-15 Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Country Status (8)

Country Link
US (2) US9133480B2 (OSRAM)
EP (1) EP2488649B1 (OSRAM)
JP (1) JP5789263B2 (OSRAM)
AU (1) AU2010306559B2 (OSRAM)
CA (1) CA2777744C (OSRAM)
DK (1) DK2488649T3 (OSRAM)
WO (1) WO2011047324A1 (OSRAM)
ZA (1) ZA201203551B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062023B2 (en) * 2006-08-25 2016-11-09 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
JP5789263B2 (ja) 2009-10-16 2015-10-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2016049492A1 (en) 2014-09-26 2016-03-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Virus-based expression vectors and uses thereof
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
US20190038659A1 (en) 2015-09-29 2019-02-07 The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing amyotrophic lateral sclerosis
CN116064669A (zh) * 2016-01-08 2023-05-05 吉奥瓦科斯公司 用于产生对肿瘤相关抗原的免疫应答的组合物和方法
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
CA3026054A1 (en) * 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
US11590219B2 (en) 2018-01-30 2023-02-28 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
JP2021523712A (ja) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法
AU2020361337B2 (en) * 2019-10-02 2025-02-06 Bionoxx Inc. Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
KR20240001116A (ko) 2021-02-02 2024-01-03 지오박스, 인크. 백신접종 동안 t-세포 프라이밍을 증진시키는 데 사용하기 위한 바이러스 구축물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EP2363143A3 (en) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
EP2062023B2 (en) 2006-08-25 2016-11-09 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
JP5789263B2 (ja) 2009-10-16 2015-10-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズＴｈｅ Ｕ．Ｓ．Ａ．Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｈｅａｌｔｈ Ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス

Also Published As

Publication number Publication date
JP5789263B2 (ja) 2015-10-07
JP2013507935A (ja) 2013-03-07
WO2011047324A1 (en) 2011-04-21
DK2488649T3 (da) 2019-06-17
US20120263750A1 (en) 2012-10-18
CA2777744C (en) 2019-09-24
US20160040135A1 (en) 2016-02-11
AU2010306559A1 (en) 2012-06-07
EP2488649A1 (en) 2012-08-22
US9879231B2 (en) 2018-01-30
US9133480B2 (en) 2015-09-15
EP2488649B1 (en) 2019-04-03
CA2777744A1 (en) 2011-04-21
AU2010306559B2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
ZA201203551B (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
EP2350525A4 (en) PHOSPHORUS AUTHENTICATION SYSTEM
EP2283418A4 (en) AUTHENTICATION WITH MULTIPLE FACTORS, MULTICANAUX
DK2459715T3 (da) Fremgangsmåde til at oprense rekombinant adamts13 og andre proteiner og sammensætninger deraf
ZA200804356B (en) Stabilizing formulations for recombinant viruses
ZA201201627B (en) Compounds as tyrosine kinase modulators
AU317301S (en) Mask prongs
IL195683A0 (en) Recombinant viral vaccine
EP2432503A4 (en) BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE
IL215599A0 (en) Papillomavirus e2 polypeptide used for vaccination
GB0807424D0 (en) Virus
GB0714578D0 (en) Viruses
EP2359182A4 (en) COLOR COMBINATOR WITH POLARIZATION CONVERSION
HUE045010T2 (hu) Térhálós poli(vinil-pirrolidon) kompozíciók
IL200073A (en) Immediate protection against pox viral infections using mva
EP2299471A4 (en) Quadrupole mass analyzer
ZA201103645B (en) Single-time vaccines
GB2461541B (en) Insulating batt with multidirectional tearability
GB0823560D0 (en) Virus
GB0813707D0 (en) Fulcrum weeder
GB0816411D0 (en) Improved methods for high field asymmetric waveform spectrometry (HiFAWS)
PH32008001041S1 (en) Blender
PH32008000904S1 (en) Urn (georgian)
ZA200810625B (en) Recombinant viral vaccine
PH32008000903S1 (en) Urn (cretan)